Array BioPharma receives first FDA approval

After twenty years, Array BioPharma has received its first two drug approvals from the FDA. The approval is for the cancer drug combo of Mektowv, a MEK inhibitor, and Braftovi, a BRAF inhibitor, will be used to treat patients with melanoma that cannot be surgically removed or has spread throughout the body.

The drugs will challenge Roche's combo of Zelboraf and Cotellic and Novartis' combo of Tafinlar and Mekinist both of which are experienced at oncology marketing and their drugs have the advantage of a head start.

Click here to view the entire article.